N/A N=958 Gestational Diabetes Mellitus Trial (GDM)
Diabetes, Gestational
Primary: Number of Participants With Composite Neonatal Morbidity — 149; 163; 62; 55 Participants — p=0.14
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=95 Early Screening and Treatment of Women With Prediabetes in Pregnancy
Diabetes · Pregnancy
Primary: Number of Patients With a Diagnosis of Gestational Diabetes at 26 Weeks Gestation. — 19; 23 Participants — p=0.32
Phase 4 N=36 Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM
Disorder of Glucose Regulation
Primary: Normalization of Glucose Levels — 9; 2; 4 Participants — p=.035
N/A N=25 Metformin Versus Insulin in Pregnant Women With Type 2 Diabetes
Pregnancy Complications
Primary: The Number of Participants Who Achieved a Hemoglobin A1C <7% — 5; 12 Participants
Phase 2 N=31 Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes
Non Insulin Dependent Diabetes · Pregnancy
Primary: Blood Glucose Measurements — 97.38; 95.04; 97.00; 92.38 mg/dL
N/A N=96 Contraception and Pregnancy in Diabetes Mellitus
Diabetes Mellitus, Type 1 · Contraception
Primary: Number of Women 'Prepared for Pregnancy\ — 3 participants
N/A N=90 Fibroblast Growth Factors 19 and 21 in Gestational Diabetes Mellitus
Gestational Diabetes Mellitus
Primary: The Concentration of Serum FGF19 — 65.96; 124.47 pg/mL
N/A N=105 Glycemic Control Using Insulin Levemir Versus Insulin NPH for Diabetes in Pregnancy
Diabetes, Gestational · Diabetes, Type 2
Primary: Glycemic Control — 109.5; 107.4 mg/dL
Phase 2 N=57 Correlation of Continuous Glucose Monitoring and Glucose Tolerance Testing With Pregnancy Outcomes
Diabetes, Gestational
Primary: Correlation Between Glucose AUC and Birth Weight. — 0.2902; 0.2935; 0.2915; 0.2859 correlation coefficient — p=0.035
Phase 4 N=54 Metabolic Analysis for Treatment Choice in Gestational Diabetes Mellitus
Gestational Diabetes · Diabetes, Gestational · Pregnancy in Diabetes
Primary: Proportion of Women Who Are Eligible, Screened, Enroll and Remain in the Study — 25; 26 Participants — p=0.9
Phase 4 N=108 Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
Diabetes Mellitus, Type 2
Primary: Number of Neonates With Composite Adverse Neonatal Outcome — 31; 35 Participants
Phase 4 N=221 Metformin Versus Insulin in Gestational Diabetes
Gestational Diabetes
Primary: Birth Weight Per Arm — 3604; 3589 g
Phase 4 N=395 Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo
Mild Gestational Diabetes
Primary: Mean Fetal Weight at Birth — 3355; 3322 grams
N/A N=106 Lipid Metabolism in Gestational Diabetes
Gestational Diabetes · Hyperlipidemia
Primary: Cholesterol — 204; 201 mg/dl
N/A N=962 Early Gestational Diabetes Screening in the Gravid Obese Woman
Gestational Diabetes · Obesity
Primary: Number of Participants With a Composite Perinatal Outcome — 235; 261 Participants
Phase 3 N=66 Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women
Diabetes Prevention in Women After GDM Who Are at High-risk
Primary: Change in Body Weight — -21.5; -12.5; -4.4 kilograms — p=<0.032
N/A N=130 Incentives and Glucose Adherence in Diabetes
Diabetes in Pregnancy
Primary: Frequency of Glucose Monitoring — 57.31; 58.48; 69.08 percentage of overall adherence
N/A N=62 Adding Metformin to Insulin in Controlling Pregestational and Gestational Diabetes Mellitus
Gestational Diabetes Mellitus in Pregnancy
Primary: Number of Participants With Glycemic Control Over Period From 20 Weeks to 36 Weeks Gestation — 24; 27 Participants
Phase 3 N=153 Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)
Gestational Diabetes Mellitus · Type 2 Diabetes Mellitus · Metabolic Syndrome
Primary: Insulin Secretion-Sensitivity Index (IS-SI) — 418.4; 333 index — p=<0.04
N/A N=814 Continuous Glucose Monitoring for Screening for Diabetes in Pregnancy
Gestational Diabetes
Primary: Number of Neonates That Show Composite Adverse Neonatal Outcome — 130; 114 Participants
N/A N=57 The Effect of Continuous Glucose Monitoring on Glycemic Control in Insulin-requiring Gestational Diabetes Mellitus
Gestational Diabetes Mellitus
Primary: Glycemic Control by Measurement of HbA1c — 5.17; 5.57 mean percentage
N/A N=16 AT GOAL: Adopting Technology for Glucose Optimization and Lifestyle in Pregnancy
Type2Diabetes · Pregnancy in Diabetic
Primary: Feasibility: Number of Participants Who Complete the Study Within 24 Month Time Period — 8; 8 Participants
N/A N=149 Metformin Compared to Glyburide in Gestational Diabetes
Gestational Diabetes
Primary: Number of Participants Assessed for Glucose Control — 50; 50 Participants
N/A N=30 Barriers to Adherence to Recommended Follow-up in Women With a History of Gestational Diabetes
Gestational Diabetes Mellitus
Primary: Weight Loss — 0; 0; 2 Participants
N/A N=60 Effect of Fibre Supplements on Gestational Diabetes
Gestational Diabetes
Primary: Numbers Diagnosed With Gestational Diabetes — 7; 6 Participants — p=0.639
N/A N=60 Fundus Findings and Thiol-Disulfide Homeostais
Gestational Diabetes · Eye Diseases · Retinal Disease
Primary: Glucose Levels of the Groups in Pregnant Women With Impaired Blood Sugar and/or Gestational DM — 111.67; 154; 83.06; 88.15 mg/dl
N/A N=18 Sleep Duration in Women With Previous Gestational Diabetes
Gestational Diabetes
Primary: Changes in Fasting Glucose — 10.4; 1.6 mg/dL
Phase 4 N=114 Metformin Postpartum for GDM RCT for Reduced Weight Retention
Diabetes, Gestational
Primary: Weight Change — 6.5; 6.3 kg
N/A N=25 Longitudinal Observation of Insulin Requirements and Sensor Use in Pregnancy
Type 1 Diabetes Mellitus · Pregnancy in Diabetics
Primary: Percentage of Time in Range Glucose Levels 63-140 mg/dL as Determined by CGM — 59 percentage of time
N/A N=921 Comparison of Two Screening Strategies for Gestational Diabetes (GDM2)
Gestational Diabetes · Pregnancy · Glucose Intolerance
Primary: Large for Gestational Age (LGA) Infant — 34; 35; 28; 34 Participants — p=0.668